Table 9.

Monitoring recommendations for antidepressants

Monitoring parameter	Agent	Frequency	Remarks
ECG for QT prolongation	TCAs	Baseline, After initial dose titration and at dose changes	More caution is indicated in children, elderly, and at higher doses
Liver function test	Agents with hepatic liability	Baseline and at 6, 12, and 24 months and when indicated	Specially in people with liver dysfunctions
BMI, Waist circumference	Agents with known weight gain liability	Baseline and 6 monthly	More caution with Mirtazapie, TCAs
Electrolytes for hyponatremia	SSRIs, SNRIs, TCAs, Mirtazapine	Baseline and after 1 month if indicated in high-risk groups, especially in >65 years age group	More frequent monitoring in renal impairment or existing hyponatremia patients
Blood Pressure monitoring	Venlafaxine, TCAs	Baseline, during titration and 3 monthly	Closer monitoring in initial periods
Sexual functioning	SSRIs	Baseline, 3 monthly	Decreased libido, premature/delayed ejaculation

BMI=Body Mass Index, ECG=Electrocardiogram, SNRI=Serotonin norepinephrine reuptake inhibitor, SSRI=Selective serotonin reuptake inhibitor, TCA=Tricyclic antidepressant